Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA4 | P22748 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 3/20 | 0.49 |
| ▸ | KRAS | P01116 | 1/20 | 0.37 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.35 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 6/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23444401 | 0.87 | JAK3 (0.39) | CA1CA2CA4CA9KRAS | |
| SCHEMBL23446088 | 0.83 | JAK3 (0.40) | CA1CA2CA4CA9OPRK1 | |
| SCHEMBL23444394 | 0.83 | JAK3 (0.40) | CA1CA2CA4CA9OPRK1 | |
| SCHEMBL23278104 | 0.82 | TEAD1 (0.34) | CA1CA2CA4CA9KRAS | |
| SCHEMBL23583942 | 0.81 | JAK3 (0.36) | CA1CA2CA4CA9JAK3 | |
| SCHEMBL22967432 | 0.80 | TEAD1 (0.36) | CA1CA2CA4CA9KRAS | |
| SCHEMBL20314912 | 0.80 | KMT2A (0.44) | MEN1KMT2A | |
| SCHEMBL23735961 | 0.79 | JAK3 (0.39) | CA1CA2CA4CA9TEAD1 | |
| SCHEMBL21610085 | 0.79 | JAK3 (0.34) | CA1CA2CA4CA9TEAD1 | |
| SCHEMBL23444404 | 0.79 | JAK3 (0.39) | CA1CA2CA4CA9TEAD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009577-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2021-01-14 | — | — | US | disclosed |
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2019-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | CA1 2659/4885CA2 2465/4885CA4 3027/4885 |
| US-20210009577-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CA1 2659/4885CA2 2465/4885CA4 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.